ArticlePharmacoEconomics2019
Expanding the Scope of Costs and Benefits for Economic Evaluations in Health: Some Words of Caution.
Article in PharmacoEconomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects.PharmacoEconomics · 2024Pooled it
- Spillover Effects on Caregivers' and Family Members' Utility: A Systematic Review of the Literature.PharmacoEconomics · 2019Pooled it
- Provider and household costs ofBulletin of the World Health Organization · 2019Trial
- Measuring health spillover effects in household members of adolescents and elderly individuals with health issues in China.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Article
- Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force.PharmacoEconomics · 2024Article
- A novel set of Austrian reference unit costs for comprehensive societal perspectives consistent with latest European costing methods for economic evaluations.Wiener klinische Wochenschrift · 2024Article
- Context-Specific Estimation of Future Unrelated Medical Costs and Their Impact on Cost-Effectiveness Analyses.PharmacoEconomics · 2023Article
- The Broader Opportunity Costs in the Broader Cost-Effectiveness Analysis Framework.Applied health economics and health policy · 2023Article
- Future Offspring Costs in Economic Evaluation.PharmacoEconomics · 2022Article
- Incorporating future unrelated medical costs in cost-effectiveness analysis in China.BMJ global health · 2021Article
- The Inclusion of Spillover Effects in Economic Evaluation: A Public Health Economics Perspective.PharmacoEconomics · 2019Article
- The Inclusion of Spillover Effects in Economic Evaluations: Not an Optional Extra.PharmacoEconomics · 2019Article
- Advances in Methods and Novel Applications for Measuring Family Spillover Effects of Illness.PharmacoEconomics · 2019Article
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
30328562What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.